PMID- 32158266
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 12
DP  - 2020
TI  - Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue 
      Sarcomas: A Retrospective Study.
PG  - 1339-1346
LID - 10.2147/CMAR.S237300 [doi]
AB  - PURPOSE: Programmed cell death 1 (PD-1) inhibitors are ineffective as monotherapy 
      for the treatment of soft tissue sarcomas (STS). However, increasing evidence 
      shows that the combination of PD-1 inhibitors and chemotherapy is efficacious and 
      safe for many types of malignancies, including STS. This study aimed to assess 
      the safety and efficacy of doxorubicin chemotherapy plus PD-1 inhibitor in the 
      treatment of metastatic STS. PATIENTS AND METHODS: We retrospectively reviewed 21 
      patients with metastatic STS who received doxorubicin chemotherapy plus a PD-1 
      inhibitor between November 2017 and October 2018. RESULTS: The objective response 
      rate was 47.6%, the disease control rate was 71.40%, and the median 
      progression-free survival was 6 months (95% CI, 2-8 months). The average change 
      in target lesion diameter from baseline was -25.15 +/- 41.61. Majority of the 
      patients experienced grade 1/2 adverse events (AEs), the grade 3/4 AEs were few. 
      The most common grade 3/4 AEs were as follows: leukopenia (23.8%) and anemia 
      (19.0%). Immune-related AEs were common and included hypothyroidism (14.3%) and 
      pneumonitiss (9.5%). No drug related deaths occurred. CONCLUSION: This study 
      provides preliminary evidence that the combination of doxorubicin chemotherapy 
      and PD-1 inhibitor for advanced STS is safe and effective. We plan to conduct 
      randomized clinical trials to confirm and characterize the activity of the 
      chemotherapy-immunotherapy combinations in the treatment of sarcomas.
CI  - (c) 2020 Tian et al.
FAU - Tian, Zhichao
AU  - Tian Z
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan Province 450008, People's Republic of 
      China.
FAU - Yang, Yonghao
AU  - Yang Y
AD  - Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou 
      University and Henan Cancer Hospital, Zhengzhou, Henan Province 450008, People's 
      Republic of China.
FAU - Yang, Jinpo
AU  - Yang J
AD  - Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou 
      University and Henan Cancer Hospital, Zhengzhou, Henan Province 450008, People's 
      Republic of China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan Province 450008, People's Republic of 
      China.
FAU - Zhang, Fan
AU  - Zhang F
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan Province 450008, People's Republic of 
      China.
FAU - Du, Xinhui
AU  - Du X
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan Province 450008, People's Republic of 
      China.
FAU - Li, Chao
AU  - Li C
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan Province 450008, People's Republic of 
      China.
FAU - Wang, Jiaqiang
AU  - Wang J
AUID- ORCID: 0000-0002-4978-1501
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan Province 450008, People's Republic of 
      China.
LA  - eng
PT  - Journal Article
DEP - 20200224
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7047982
OTO - NOTNLM
OT  - camrelizumab
OT  - doxorubicin
OT  - immunotherapy
OT  - pembrolizumab
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/03/12 06:00
MHDA- 2020/03/12 06:01
PMCR- 2020/02/24
CRDT- 2020/03/12 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/02/14 00:00 [accepted]
PHST- 2020/03/12 06:00 [entrez]
PHST- 2020/03/12 06:00 [pubmed]
PHST- 2020/03/12 06:01 [medline]
PHST- 2020/02/24 00:00 [pmc-release]
AID - 237300 [pii]
AID - 10.2147/CMAR.S237300 [doi]
PST - epublish
SO  - Cancer Manag Res. 2020 Feb 24;12:1339-1346. doi: 10.2147/CMAR.S237300. 
      eCollection 2020.